{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:01:25Z","timestamp":1791853285413,"version":"4.3.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The SURMOUNT-OSA trial evaluated the impact of the weight loss drug tirzepatide in obese patients with obstructive sleep apnea (OSA). The primary endpoint assessed was a change in the apnea-hypopnea index (AHI) after 52 weeks in individuals on the drug compared to placebo. There were robust decrements in AHI with resolution of OSA in approximately 50% of subjects. These impressive results raise the question: what role will this medication play in routine management of OSA? This Forum article asked four opinion leaders to give their views. All agreed that tirzepatide will play a major role, but there were different opinions as to what that role will be. There was a fairly broad view that the role in primary treatment would be limited, given how long it takes to get an effect, whereas CPAP gives immediate benefit. Thus, initially the drug will likely be used in concert with CPAP. After weight loss is achieved, there will be consideration as to whether CPAP can be stopped. Opinion leaders argued that there are opportunities for treatment of obesity hypoventilation syndrome that require study. Other primary outcomes need to be investigated as well. Moreover, studies comparing drug treatment with CPAP need to be considered. The high cost of the drug could increase already existing disparities in care. There are concerns about long-term adherence, but current data are largely about the initial drugs of this type. In conclusion, the precise guidelines for optimal tirzepatide use in OSA remain to be determined.<\/jats:p>","DOI":"10.1093\/sleep\/zsaf045","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:39:15Z","timestamp":1743273555000},"source":"Crossref","is-referenced-by-count":13,"title":["What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2879-0484","authenticated-orcid":false,"given":"Allan","family":"Pack","sequence":"first","affiliation":[{"name":"Division of Sleep Medicine\/Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]},{"name":"Chronobiology and Sleep Institute, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Grunstein","sequence":"additional","affiliation":[{"name":"Woolcock Institute of Medical Research, Macquarie University , Sydney ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney ,","place":["Australia"]},{"name":"RPA-Charles Perkins Centre Clinic, Royal Prince Alfred Hospital , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-5433","authenticated-orcid":false,"given":"Babak","family":"Mokhlesi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Rush University Medical Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0963-255X","authenticated-orcid":false,"given":"Silke","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pulmonary and Sleep Disorders Unit, St. Vincent\u2019s University Hospital , Dublin ,","place":["Ireland"]},{"name":"School of Medicine, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schwab","sequence":"additional","affiliation":[{"name":"Division of Sleep Medicine\/Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]},{"name":"Chronobiology and Sleep Institute, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8195-6036","authenticated-orcid":false,"given":"David","family":"Gozal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Office of the Dean, Joan C. Edwards School of Medicine, Marshall University , Huntington, WV ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"13","key":"2025061301514256800_CIT0001","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med."},{"issue":"17","key":"2025061301514256800_CIT0002","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1056\/NEJM199304293281704","article-title":"The occurrence of sleep-disordered breathing among middle-aged adults","volume":"328","author":"Young","year":"1993","journal-title":"N Engl J Med."},{"issue":"2","key":"2025061301514256800_CIT0003","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/sleep\/19.2.104","article-title":"Obesity and weight loss in obstructive sleep apnea: a critical review","volume":"19","author":"Strobel","year":"1996","journal-title":"Sleep."},{"issue":"6","key":"2025061301514256800_CIT0004","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s11325-023-02840-1","article-title":"Bariatric surgery and obstructive sleep apnea: a systematic review and meta-analysis","volume":"27","author":"Al Oweidat","year":"2023","journal-title":"Sleep Breath"},{"issue":"11","key":"2025061301514256800_CIT0005","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/2012.jama.11580","article-title":"Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial","volume":"308","author":"Dixon","year":"2012","journal-title":"JAMA."},{"issue":"10","key":"2025061301514256800_CIT0006","doi-asserted-by":"publisher","first-page":"zsad224","DOI":"10.1093\/sleep\/zsad224","article-title":"Giving weight to incretin-based pharmacotherapy for obesity","volume":"46","author":"Grunstein","year":"2023","journal-title":"Sleep."},{"key":"2025061301514256800_CIT0007","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit\u2013harm modelling study","volume":"73","author":"Moll","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2025061301514256800_CIT0008","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2337\/dca24-0034","article-title":"Regional heterogeneity of the results of glucagon-like peptide 1 receptor agonist trials in type 2 diabetes: a reanalysis of individual participant data","volume":"47","author":"Jullien","year":"2024","journal-title":"Diabetes Care."},{"key":"2025061301514256800_CIT0009","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/17446651.2024.2395540","article-title":"Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management","volume":"19","author":"Rabbani","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2025061301514256800_CIT0010","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ahj.2024.08.015","article-title":"Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque","volume":"278","author":"Hamid","year":"2024","journal-title":"Am Heart J."},{"issue":"6","key":"2025061301514256800_CIT0011","doi-asserted-by":"publisher","first-page":"qxae055","DOI":"10.1093\/haschl\/qxae055","article-title":"Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program","volume":"2","author":"Kim","year":"2024","journal-title":"Health Affairs Scholar"},{"issue":"5","key":"2025061301514256800_CIT0012","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1113\/jphysiol.1902.sp000920","article-title":"The mechanism of pancreatic secretion","volume":"28","author":"Bayliss","year":"1902","journal-title":"J Physiol."},{"key":"2025061301514256800_CIT0013","article-title":"Continuous positive airway pressure for sleep apnea","volume-title":"Principles and Practice of Sleep Medicine","author":"Sullivan","year":"1989"},{"issue":"5","key":"2025061301514256800_CIT0014","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/jcm10050936","article-title":"CPAP therapy termination rates by OSA phenotype: a French nationwide database analysis","volume":"10","author":"Pepin","year":"2021","journal-title":"J Clin Med"},{"key":"2025061301514256800_CIT0015","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1016\/j.sleep.2023.11.1022","article-title":"Real world assessment of reduction of obstructive sleep apnea events by continuous positive airway pressure using a continuous large U.S. sample by home under-mattress devices","volume":"115","author":"Kushida","year":"2024","journal-title":"Sleep Med."},{"key":"2025061301514256800_CIT0016","doi-asserted-by":"publisher","first-page":"105015","DOI":"10.1016\/j.ebiom.2024.105015","article-title":"CPAP may promote an endothelial inflammatory milieu in sleep apnoea after coronary revascularization","volume":"101","author":"Peker","year":"2024","journal-title":"EBioMedicine"},{"issue":"6","key":"2025061301514256800_CIT0017","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5664\/jcsm.11030","article-title":"Long-term effects on clinical event, mental health, and related outcomes of CPAP for obstructive sleep apnea: a systematic review","volume":"20","author":"Balk","year":"2024","journal-title":"J Clin Sleep Med."},{"issue":"15","key":"2025061301514256800_CIT0018","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell."},{"issue":"7","key":"2025061301514256800_CIT0019","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-2600(23)00469-1","article-title":"Continuous positive airway pressure is here to stay","volume":"12","author":"Malhotra","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"8","key":"2025061301514256800_CIT0020","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)."},{"issue":"10403","key":"2025061301514256800_CIT0021","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet."},{"issue":"18","key":"2025061301514256800_CIT0022","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.2024.1017","article-title":"Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions","volume":"331","author":"Rubin","year":"2024","journal-title":"JAMA."},{"issue":"151","key":"2025061301514256800_CIT0023","doi-asserted-by":"publisher","first-page":"180097","DOI":"10.1183\/16000617.0097-2018","article-title":"Obesity hypoventilation syndrome","volume":"28","author":"Masa","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"10182","key":"2025061301514256800_CIT0024","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(18)32978-7","article-title":"Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial","volume":"393","author":"Masa","year":"2019","journal-title":"Lancet."},{"issue":"3","key":"2025061301514256800_CIT0025","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jsmc.2014.05.007","article-title":"Obesity hypoventilation syndrome epidemiology and diagnosis","volume":"9","author":"Balachandran","year":"2014","journal-title":"Sleep Med Clin"},{"issue":"7","key":"2025061301514256800_CIT0026","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7326\/M14-2238","article-title":"Efficacy of commercial weight-loss programs: an updated systematic review","volume":"162","author":"Gudzune","year":"2015","journal-title":"Ann Intern Med."},{"issue":"2","key":"2025061301514256800_CIT0027","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med."},{"issue":"1","key":"2025061301514256800_CIT0028","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1464-5491.2012.03750.x","article-title":"Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study","volume":"30","author":"Orchard","year":"2013","journal-title":"Diabet Med."},{"issue":"4","key":"2025061301514256800_CIT0029","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1513\/AnnalsATS.201907-554OC","article-title":"Weight loss interventions as treatment of obesity hypoventilation syndrome. a systematic review","volume":"17","author":"Kakazu","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"2025061301514256800_CIT0030","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2025061301514256800_CIT0031","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med."},{"issue":"12","key":"2025061301514256800_CIT0032","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med."},{"issue":"2","key":"2025061301514256800_CIT0033","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"4","key":"2025061301514256800_CIT0034","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"2025061301514256800_CIT0035","doi-asserted-by":"publisher","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025061301514256800_CIT0036","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA."},{"issue":"6","key":"2025061301514256800_CIT0037","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity \u2013 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med."},{"issue":"10","key":"2025061301514256800_CIT0038","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"2025061301514256800_CIT0039","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1164\/rccm.201601-0088OC","article-title":"Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA randomized controlled trial","volume":"194","author":"Peker","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"2025061301514256800_CIT0040","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2213-2600(19)30271-1","article-title":"Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial","volume":"8","author":"Sanchez-de-la-Torre","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2025061301514256800_CIT0041","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1378\/chest.13-0179","article-title":"CPAP improves endothelial function in patients with minimally symptomatic OSA: results from a subset study of the MOSAIC trial","volume":"144","author":"Kohler","year":"2013","journal-title":"Chest."},{"issue":"6","key":"2025061301514256800_CIT0042","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/resp.12573","article-title":"Effect of CPAP therapy on endothelial function in obstructive sleep apnoea: a systematic review and meta-analysis","volume":"20","author":"Schwarz","year":"2015","journal-title":"Respirology."},{"issue":"3","key":"2025061301514256800_CIT0043","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1513\/AnnalsATS.202309-821OC","article-title":"Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study","volume":"21","author":"O\u2019Donnell","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"2025061301514256800_CIT0044","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2025061301514256800_CIT0045","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA."},{"issue":"24","key":"2025061301514256800_CIT0046","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med."},{"issue":"4","key":"2025061301514256800_CIT0047","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index &gt;\/=27 kg\/m(2): SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension."},{"issue":"6","key":"2025061301514256800_CIT0048","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"2025061301514256800_CIT0049","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"2025061301514256800_CIT0050","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5664\/jcsm.1928","article-title":"The AASM scoring manual four years later","volume":"8","author":"Grigg-Damberger","year":"2012","journal-title":"J Clin Sleep Med."},{"issue":"10","key":"2025061301514256800_CIT0051","doi-asserted-by":"publisher","first-page":"e46490","DOI":"10.7759\/cureus.46490","article-title":"Effect on Hemoglobin A1c (HbA1c) and body weight after discontinuation of tirzepatide, a novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist: a single-center case series study","volume":"15","author":"Kubota","year":"2023","journal-title":"Cureus"},{"issue":"24","key":"2025061301514256800_CIT0052","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMoa1306187","article-title":"CPAP, weight loss, or both for obstructive sleep apnea","volume":"370","author":"Chirinos","year":"2014","journal-title":"N Engl J Med."},{"issue":"6","key":"2025061301514256800_CIT0053","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.chest.2019.01.012","article-title":"Adherence to CPAP: what should we be aiming for, and how can we get there","volume":"155","author":"Bakker","year":"2019","journal-title":"Chest."}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaf045\/62871661\/zsaf045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/48\/6\/zsaf045\/62871661\/zsaf045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/48\/6\/zsaf045\/62871661\/zsaf045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:51:50Z","timestamp":1749793910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaf045\/8106477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,4]]},"published-print":{"date-parts":[[2025,6,13]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaf045","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,4]]},"article-number":"zsaf045"}}